))
Bright Minds Biosciences & Next Generation Psychedelics
Manage episode 337249293 series 3380517
Content provided by Encode Ideas, L.P., Encode Ideas, and L.P.. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Encode Ideas, L.P., Encode Ideas, and L.P. or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
An interview with Gideon Shapiro, Co-Founder & VP of Discovery at Bright Minds Biosciences, where we discuss recent and upcoming events in psychedelic drug development. We cover Bright Minds pipeline of 5HT2 agonists, the importance of FDA's approval of Spravato, and Compass's impending Ph2b psilocybin data, among other topics relevant in the psychedelic space.
Companies discussed during the podcast:
- Bright Minds Biosciences Inc. (CSE: DRUG/OTCQB: BMBIF)
- Compass Pathways plc (Nasdaq: CMPS)
- Cybin Inc. (NYSE: CYBN)
- Xenon Pharmaceuticals Inc. (Nasdaq: XENE)
- Johnson & Johnson (NYSE: JNJ)
7 episodes
Share
